NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Vaccine Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Cancer Vaccines



Researchers from National Institutes of Health describe findings in cancer vaccines



September 10th, 2008

Current study results from the report, 'Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant,' have been published. "We have previously reported on the safety and immunologic response of a poxvirus-based vaccine encoding prostate-specific antigen (PSA) used in combination with radiation therapy in patients with localized prostate cancer. We hypothesized that a 'metronomic' dose of interleukin 2 (IL-2) as a biological adjuvant would cause less toxicity while maintaining immunologic response," scientists writing in the journal Clinical Cancer Research...


Source: Vaccine Weekly (2008-09-10)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login